Compare MSM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSM | SRRK |
|---|---|---|
| Founded | 1941 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 1996 | 2018 |
| Metric | MSM | SRRK |
|---|---|---|
| Price | $106.72 | $48.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $96.20 | $56.17 |
| AVG Volume (30 Days) | 519.4K | ★ 1.2M |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $3,363,817,000.00 | N/A |
| Revenue This Year | $5.82 | N/A |
| Revenue Next Year | $5.26 | $534.24 |
| P/E Ratio | $63.17 | ★ N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $77.78 | $27.07 |
| 52 Week High | $107.99 | $51.63 |
| Indicator | MSM | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 68.36 | 59.13 |
| Support Level | $82.88 | $45.42 |
| Resistance Level | N/A | $51.30 |
| Average True Range (ATR) | 2.66 | 2.01 |
| MACD | 0.38 | 0.08 |
| Stochastic Oscillator | 91.37 | 78.00 |
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.